Altamira Therapeutics Ltd
CYTO
CYTO was delisted on the 19th of December, 2024.
4 hedge funds and large institutions have $9.8M invested in Altamira Therapeutics Ltd in 2016 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and 0 closing their positions.
350% more capital inflows, than outflows
Capital inflows: $7.24M | Capital outflows: $1.61M
33% more funds holding
Funds holding: 3 → 4 (+1)
26.55% more ownership
Funds ownership: 0% → 26.55% (+27%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $17K
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wasatch Advisors
Salt Lake City,
Utah
|
-$1.59M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$18K |
| 3 |
Citigroup
New York
|
-$3K |
CYTO Hedge Fund Activity: Q4 2016 in Review
4 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Altamira Therapeutics Ltd (CYTO) for Q4 2016, worth a combined $9.8M — up 26% from $7.74M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new CYTO positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest seller was Wasatch Advisors, cutting an estimated $1.59M.
- 4 institutional investors held Altamira Therapeutics Ltd (CYTO) as of Q4 2016, up from 3 in Q3 2016.
- Funds reported $9.8M of Altamira Therapeutics Ltd stock for Q4 2016, up 26% quarter-over-quarter.
- 1 fund opened new Altamira Therapeutics Ltd positions in Q4 2016 and 0 closed out, a net change of +1 holder.
- The largest Altamira Therapeutics Ltd seller in Q4 2016 was Wasatch Advisors, an estimated $1.59M sold.
Based on aggregated 13F filings for Q4 2016.